Showing 4631-4640 of 6036 results for "".
- Zeiss Ventures Invests in Morrow Eyewearhttps://modernod.com/news/zeiss-ventures-invests-in-morrow-eyewear/2480961/Zeiss Ventures has invested in Morrow, a high-tech start-up from Belgium developing autofocal glasses that allow people to switch between near vision and distance vision at the touch of a button. The innovative liquid crystal technology is embedded between two ultra-precise, thin-c
- Bausch + Lomb Announces Efficiency-Enhancing Upgrades for Stellaris Elite Vision Enhancement Systemhttps://modernod.com/news/bausch-lomb-announces-efficiency-enhancing-upgrades-for-stellaris-elite-vision-enhancement-system/2480960/Bausch + Lomb announced the first in a series of upgrades for the Stellaris Elite vision enhancement system designed to enhance efficiency. The upgrades include an increase to the maximum vacuum setting from 600 to 660 mmHg and an enhancement to the removable valve caps in the troc
- Study: AMD Strongly Associated With Heart Disease and Strokehttps://modernod.com/news/study-blinding-eye-disease-is-strongly-associated-with-heart-disease-and-stroke/2480958/Patients with a specific form of age-related macular degeneration (AMD) are at significant risk for cardiovascular disease and stroke, according to new research from New York Eye and Ear Infirmary of Mount Sinai. This study, published in the July issue of Retina, is the first t
- Samsara Vision Announces First US Surgeries of the SING IMT for AMD as Part of the CONCERTO Studyhttps://modernod.com/news/samsara-vision-announces-first-us-surgeries-of-the-sing-imt-for-aamd-as-part-of-the-concerto-study/2480955/Samsara Vision announced the completion of the first US surgeries of its SING IMT (Smaller-Incision New-Generation Implantable Miniature Telescope), as part of the CONCERTO clinical study, a US-based FDA study to evaluate improvements in visual acuity and safety of the device
- RetinalGeniX Technologies Acquires DNA/GPS Inc.https://modernod.com/news/retinalgenix-technologies-acquires-dnagps-inc/2480949/RetinalGeniX Technologies announced the acquisition of DNA/GPS. Terms of the deal were not disclosed. The acquisition gives RetinalGeniX the rights to the platform technology designed by Larry Perich, MD, which is designed to al
- OliX Pharmaceuticals Announces IND Submission to FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trialhttps://modernod.com/news/olix-pharmaceuticals-announces-ind-submission-to-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial/2480945/OiX Pharmaceuticals announced the submission of an investigational new drug (IND) application to the FDA to evaluate the safety and tolerability of OLX10212 for the treatment of advanced age-related macular degeneration (AMD). The objective of this phase 1 study is to determine the safety an
- NPR Report: He and His Wife Both Got Cataract Surgery. His Bill Was 20 times Higher Than Hershttps://modernod.com/news/npr-report-he-and-his-wife-both-got-cataract-surgery-his-bill-was-20-times-higher-than-hers/2480934/A NPR report shares an example of the factors involved in how insurance companies determine reimbursement for cataract surgery. The articl
- LumiThera Presents New Data from LIGHTSITE III Trial Showing Improvement in Vision in Intermediate Dry AMDhttps://modernod.com/news/lumithera-presents-new-data-from-lightsite-iii-trial-showing-improvement-in-vision-in-intermediate-dry-amd/2480930/LumiThera announced detailed findings in its LIGHTSITE III, multicenter clinical trial in non-neovascular age-related macular degeneration (AMD) subjects treated with photobiomodulation (PBM) using the Valeda Light Delivery System. LIGHTSITE III, a prospective, double-masked,
- BRIM Biotechnology Enters Trading in Taiwanhttps://modernod.com/news/brim-biotechnology-enters-otc-trading-in-taiwan/2480926/BRIM Biotechnology has entered OTC trading in Taiwan on June 23, 2022. Established in 2013, BRIM is a clinical-stage company developing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases. BRIM has several novel drug products
- Opus Genetics Appoints Ben Yerxa, PhD, as Permanent Chief Executive Officerhttps://modernod.com/news/opus-genetics-appoints-ben-yerxa-phd-as-permanent-chief-executive-officer/2480923/Opus Genetics announced the appointment of Ben Yerxa, PhD, as Chief Executive Officer. Dr. Yerxa previously served as acting CEO of Opus, in addition to former roles as CEO of the Foundation Fighting Blindness and the Retinal Degeneration (RD) Fund, the venture arm of th